Chemokine and lymph node homing receptor expression on pDC vary by graft source.
A randomized clinical trial of BM vs. blood stem cell transplants from unrelated donors showed that more plasmacytoid dendritic cells (pDCs) in BM grafts was associated with better post-transplant survival. Here, we describe differences in homing-receptor expression on pDC to explain observed differences following BM vs. blood stem cell transplantation.
Department of Hematology and Medical Oncology; Division of Stem Cell and Bone Marrow Transplantation; Winship Cancer Institute; Emory University School of Medicine ; Atlanta, GA USA.
Sakura
S
Hosoba
Department of Hematology and Medical Oncology; Division of Stem Cell and Bone Marrow Transplantation; Winship Cancer Institute; Emory University School of Medicine ; Atlanta, GA USA.
Wayne Ac
WA
Harris
Department of Hematology and Medical Oncology; Division of Stem Cell and Bone Marrow Transplantation; Winship Cancer Institute; Emory University School of Medicine ; Atlanta, GA USA.
Kaifeng L
KL
Lin
Department of Hematology and Medical Oncology; Division of Stem Cell and Bone Marrow Transplantation; Winship Cancer Institute; Emory University School of Medicine ; Atlanta, GA USA.
Edmund K
EK
Waller
APC, antigen presenting cell; BDCA, blood dendritic cell antigen; BM, bone marrow; BMTCTN, Bone Marrow Transplantation Clinical Trial Network; CCR, C chemokine receptor; CD, cluster of differentiation; CXCR, CX chemokine receptor; G-CSF, granulocyte colony stimulating factor; GVHD, graft vs. host disease; GVL, graft vs. leukemia; HEV, high endothelial venule; HLA-DR, human lymphocyte antigen-DR; IRB, institutional review board; Lin, lineage; PAM, pathogen associated molecular; PB, peripheral blood; PRR, pattern recognition receptor; allo-HSCT, allogeneic hematopoietic stem cell transplantation; antigen presenting; chemokine receptor; graft reject; graft vs. host disease; graft vs. leukemia effect; pDC, plasmacytoid dendritic cell; plasmacytoid dendritic cell; stem cell transplantation